Clinical Trials Logo

Clinical Trial Summary

Phase 2, randomised, double-blind,double-dummy study in hospitalised adults with complicated urinary tract infection (cUTI), including acute pyelonephritis.Treatment duration for each cohort was 7 to 14 days. Patients were not permitted to switch to oral therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05060419
Study type Interventional
Source Qilu Pharmaceutical Co., Ltd.
Contact Ju Yunfei, MM
Phone +86-0531-55821309
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date October 8, 2021
Completion date August 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04979806 - Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3
Recruiting NCT02537847 - Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli Phase 2
Completed NCT02166476 - Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Phase 3
Completed NCT03757234 - IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis Phase 2
Completed NCT02420366 - Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Recruiting NCT04654507 - Efficacy of Corticosteroids in Reducing the Renal Scarring in Acute Pyelonephritis in Children Phase 3
Recruiting NCT04686318 - Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis
Recruiting NCT04667195 - Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis
Completed NCT03788967 - Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3
Completed NCT02168946 - Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Phase 3
Completed NCT01096849 - A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) Phase 2
Completed NCT03445195 - Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections Phase 2
Completed NCT02486627 - A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) Phase 3
Completed NCT03477422 - CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria Phase 3
Completed NCT01928433 - Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Phase 2
Recruiting NCT03840148 - Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections Phase 3
Recruiting NCT04882085 - Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Phase 4
Withdrawn NCT03630081 - Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3
Completed NCT02753946 - Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections Phase 2/Phase 3
Completed NCT02034851 - Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection